Frost Radar：人工智慧驱动的药物发现，2025 年

Frost Radar: AI-Enabled Drug Discovery, 2025

出版日期: 2025年12月12日 | 出版商:

Frost & Sullivan | 英文 62 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

鼓励企业采取行动（C2A）的标竿管理体系－创新能加速新业务的创造与成长。

长期以来，由于大量生物数据的处理和解读极为复杂，针对未满足医疗需求的疾病发现新的药物标靶一直面临挑战。临床和研究数据的数量和可靠性不断提高，使得云端运算、人工智慧、机器学习、自然语言处理和进阶分析等辅助工具和技术的应用变得至关重要。这促使药物发现和开发从传统的、缓慢的方法转向相对快速、精简且数据驱动的方法。为了保持竞争力，产业相关人员必须在数据、人工智慧和运算能力之间找到合适的平衡点，并将其与湿实验室能力相协调。由于药物发现主要涉及对生物网络和药物-靶点相互作用的理解，因此人工智慧被无缝集成，以实现对特异性疾病未满足治疗靶点的识别和优先排序。供应商与产业的伙伴关係持续扩展，特别着重于发现用于治疗肿瘤、神经系统疾病、老龄化和罕见疾病的新型化合物。许多成熟的公司已经拥有成功的临床阶段分子，这些分子或是透过与製药公司合作开发和授权协议来获得，或透过内部研发获得。

Frost & Sullivan公司对产业内的众多公司进行分析。公司根据其领导力及其他特征进行筛选，然后根据十项成长和创新标准进行基准测试，以确定其在弗若斯特阶梯上的位置。本出版品为每家公司提供一份弗若斯特阶梯上的竞争概况，其中考虑了公司的优势以及最能发挥这些优势的机会。

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natural language processing, and advanced analytics, to make the shift from the slow, traditional approach to drug discovery and development to one that is relatively fast, rational, and data-driven. To remain competitive, industry players need to establish the right balance of data, AI, and computational capability and match it with the wet lab capability. With drug discovery being primarily about understanding biological networks and drug-target interactions, AI has been seamlessly integrating itself to allow identification and prioritization of disease-specific unmet therapeutic targets. Vendor/pharmaceutical industry partnerships continue to grow, with a focus on discovery of novel compounds for treatments related to oncology, neurological conditions, aging, and rare diseases. Most established companies have successful clinical-stage molecules either in co-development/licensing agreements with pharma or developed in-house.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.